2010 will be marked by actively seeking growth in the level of its activity without ignoring margins.
Generally the group will continue its constant efforts to improve its management efficiency...

 

Since its creation in 1962, PCAS’ aim has been to actively participate in the
progress of science.
It achieves this, first of all, in the field of health, by being involved in the development and manufacture of active chemical ingredients which are key to medicines. This activity is carried out either by working in partnership with pharmaceutical laboratories or alone.
However, PCAS also achieves this in the automotive, ecological housing, cosmetic and perfumery fields.
PCAS works closely with a number of renowned research centres, both public or private, French and foreign, through approximately 100 of its own researchers, its R&D centres and its 9 industrial sites. PCAS carries out leading-edge research, not basic research. However, PCAS intends to develop more and more molecules and its own proprietary products.

 

PCAS is a community of around 900 people who share the same strong values: work meticulously, satisfaction and respect for its partners, constant improvement to the efficiency of its industrial performance, personnel and site safety, corporate spirit…
Its business is world-wide and its sectors of interest are at the heart of the economy.
2009 was of course marked, as it was for all economic players, be they small or large, by the crisis which was particularly felt from the second half of 2008. Measures were quickly taken to adapt to the circumstances, after careful consideration. This phase has now been overcome and essentially completed. 2010 will be marked by actively seeking growth in the level of its activity without ignoring margins. It will focus predominately on geographical developments and extending its
new product range. These growth factors and the ambition are detailed on the following pages.
Generally the group will continue its constant efforts to improve its management efficiency in a yet still unstable environment. Productivity investments are currently being reviewed and will be executed as and when requirements are firmed up. Our R&D teams will continue to be the spear-head in our commercial activities
world-wide.

 

I thank all our teams for their dedication and congratulate them for their courage.